334 related articles for article (PubMed ID: 11525221)
1. Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children.
Tollemar J; Klingspor L; Ringdén O
Clin Microbiol Infect; 2001; 7 Suppl 2():68-79. PubMed ID: 11525221
[TBL] [Abstract][Full Text] [Related]
2. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.
Coukell AJ; Brogden RN
Drugs; 1998 Apr; 55(4):585-612. PubMed ID: 9561346
[TBL] [Abstract][Full Text] [Related]
3. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
4. High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
Mehta P; Vinks A; Filipovich A; Vaughn G; Fearing D; Sper C; Davies S
Biol Blood Marrow Transplant; 2006 Feb; 12(2):235-40. PubMed ID: 16443521
[TBL] [Abstract][Full Text] [Related]
5. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients.
Tollemar J; Ringdén O; Andersson S; Sundberg B; Ljungman P; Tydén G
Bone Marrow Transplant; 1993 Dec; 12(6):577-82. PubMed ID: 8136741
[TBL] [Abstract][Full Text] [Related]
6. A retrospective clinical comparison between antifungal treatment with liposomal amphotericin B (AmBisome) and conventional amphotericin B in transplant recipients.
Tollemar J; Andersson S; Ringdén O; Tydén G
Mycoses; 1992; 35(9-10):215-20. PubMed ID: 1291871
[TBL] [Abstract][Full Text] [Related]
7. Ten years' experience with liposomal amphotericin B in transplant recipients at Huddinge University Hospital.
Ringdén O
J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():51-5. PubMed ID: 11801582
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients.
Walsh TJ; Yeldandi V; McEvoy M; Gonzalez C; Chanock S; Freifeld A; Seibel NI; Whitcomb PO; Jarosinski P; Boswell G; Bekersky I; Alak A; Buell D; Barret J; Wilson W
Antimicrob Agents Chemother; 1998 Sep; 42(9):2391-8. PubMed ID: 9736569
[TBL] [Abstract][Full Text] [Related]
9. AmBisome (liposomal amphotericin B): a comparative review.
Boswell GW; Buell D; Bekersky I
J Clin Pharmacol; 1998 Jul; 38(7):583-92. PubMed ID: 9702842
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients.
Ringdén O; Meunier F; Tollemar J; Ricci P; Tura S; Kuse E; Viviani MA; Gorin NC; Klastersky J; Fenaux P
J Antimicrob Chemother; 1991 Oct; 28 Suppl B():73-82. PubMed ID: 1778894
[TBL] [Abstract][Full Text] [Related]
11. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group.
Wolff SN; Fay J; Stevens D; Herzig RH; Pohlman B; Bolwell B; Lynch J; Ericson S; Freytes CO; LeMaistre F; Collins R; Pineiro L; Greer J; Stein R; Goodman SA; Dummer S
Bone Marrow Transplant; 2000 Apr; 25(8):853-9. PubMed ID: 10808206
[TBL] [Abstract][Full Text] [Related]
12. Use of liposomal amphotericin B in bone marrow transplant.
Sastry PS; Parikh PM; Kulkarni PS; Bhagwat R; Gadade H
J Postgrad Med; 2005; 51 Suppl 1():S49-52. PubMed ID: 16519256
[TBL] [Abstract][Full Text] [Related]
13. Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer.
Groll AH; Müller FM; Piscitelli SC; Walsh TJ
Klin Padiatr; 1998; 210(4):264-73. PubMed ID: 9743964
[TBL] [Abstract][Full Text] [Related]
14. Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B.
Krüger WH; Rüssmann B; de Wit M; Kröger N; Renges H; Sobottka I; Zander AR
Acta Haematol; 2005; 113(2):104-8. PubMed ID: 15802888
[TBL] [Abstract][Full Text] [Related]
15. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
[TBL] [Abstract][Full Text] [Related]
16. Lipid formulations of amphotericin B.
Dix SP; Andriole VT
Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
[TBL] [Abstract][Full Text] [Related]
17. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study.
Tollemar J; Höckerstedt K; Ericzon BG; Jalanko H; Ringdén O
Transplantation; 1995 Jan; 59(1):45-50. PubMed ID: 7839427
[TBL] [Abstract][Full Text] [Related]
18. Liposomal amphotericin B, AmBisome.
Hay RJ
J Infect; 1994 May; 28 Suppl 1():35-43. PubMed ID: 8077689
[TBL] [Abstract][Full Text] [Related]
19. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study.
Kelsey SM; Goldman JM; McCann S; Newland AC; Scarffe JH; Oppenheim BA; Mufti GJ
Bone Marrow Transplant; 1999 Jan; 23(2):163-8. PubMed ID: 10197802
[TBL] [Abstract][Full Text] [Related]
20. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
Brogden RN; Goa KL; Coukell AJ
Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]